We are live on ! Find out more
CRBU icon

Caribou Biosciences

93 hedge funds and large institutions have $465M invested in Caribou Biosciences in 2021 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 32 increasing their positions, 11 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

191% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 11

23% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 22

12% more call options, than puts

Call options by funds: $843K | Put options by funds: $754K

6% more funds holding

Funds holding: 8893 (+5)

1.48% more ownership

Funds ownership: 50.13%51.61% (+1.5%)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

34% less capital invested

Capital invested by funds: $704M → $465M (-$240M)

Holders
93
Holders Change
+5
Holders Change %
+5.68%
% of All Funds
1.43%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.06%
New
27
Increased
32
Reduced
11
Closed
22
Calls
$843K
Puts
$754K
Net Calls
+$89K
Net Calls Change
+$89K
Name Holding Trade Value Shares
Change
Change in
Stake
VCIM
26
Velan Capital Investment Management
Georgia
$3.18M +$4.1M +210,695 New
Northern Trust
27
Northern Trust
Illinois
$2.78M +$216K +11,086 +6%
SCM
28
Shelton Capital Management
Colorado
$2.75M +$856K +44,000 +32%
Mirae Asset Global Investments
29
Mirae Asset Global Investments
South Korea
$2.7M +$3.48M +178,913 New
Citadel Advisors
30
Citadel Advisors
Florida
$2.28M +$2.94M +151,110 New
Charles Schwab
31
Charles Schwab
California
$2.15M +$180K +9,239 +7%
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$2.13M +$2.75M +141,361 New
LCM
33
Laurion Capital Management
New York
$1.74M
Morgan Stanley
34
Morgan Stanley
New York
$1.56M +$978K +50,312 +95%
Renaissance Technologies
35
Renaissance Technologies
New York
$1.45M +$1.87M +95,949 New
Bank of America
36
Bank of America
North Carolina
$1.36M +$1.08M +55,767 +162%
GIM
37
Granahan Investment Management
Massachusetts
$1.24M -$1.16M -59,824 -42%
Victory Capital Management
38
Victory Capital Management
Texas
$1.23M -$73.3K -3,770 -4%
Squarepoint
39
Squarepoint
New York
$1.16M +$32.9K +1,691 +2%
EC
40
EcoR1 Capital
California
$1.13M
WP
41
Woodline Partners
California
$1.04M -$982K -50,471 -42%
Bank of New York Mellon
42
Bank of New York Mellon
New York
$1.02M +$383K +19,704 +41%
SAM
43
Stansberry Asset Management
Texas
$1.02M +$779K +40,047 +147%
N
44
Nuveen
North Carolina
$1.01M -$58.5K -3,007 -5%
Ensign Peak Advisors
45
Ensign Peak Advisors
Utah
$978K +$1.26M +64,788 New
VIA
46
Vident Investment Advisory
Georgia
$910K +$1.17M +60,306 New
Swiss National Bank
47
Swiss National Bank
Switzerland
$797K +$1.03M +52,800 New
PVI
48
Pura Vida Investments
New York
$633K -$33.2K -1,707 -4%
E
49
Ergoteles
New York
$626K +$807K +41,487 New
GAA
50
Green Alpha Advisors
Colorado
$537K +$53.6K +2,756 +8%

CRBU Hedge Fund Activity: Q4 2021 in Review

93 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q4 2021, worth a combined $465M — down 34% from $704M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CRBU positions and 22 closed out — a net gain of 5 holders — while 32 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $11.3M. The largest seller was Jennison Associates, exiting entirely with an estimated $7.69M sold.

  • 93 institutional investors held Caribou Biosciences (CRBU) as of Q4 2021, up from 88 in Q3 2021.
  • Funds reported $465M of Caribou Biosciences stock for Q4 2021, down 34% quarter-over-quarter.
  • 27 funds opened new Caribou Biosciences positions in Q4 2021 and 22 closed out, a net change of +5 holders.
  • The largest Caribou Biosciences buyer in Q4 2021 was BlackRock, an estimated $11.3M added.
  • The largest Caribou Biosciences seller in Q4 2021 was Jennison Associates, an estimated $7.69M sold.

Based on aggregated 13F filings for Q4 2021.